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Background: Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy are rare
diseases with no known coherence.
Case Presentation: A daughter and her biological mother were diagnosed with pregnancy-induced thrombotic
microangiopathy and anti-glomerular basement membrane glomerulonephritis, respectively. Both developed
end-stage renal disease. Exploration of a common aetiology included analyses of HLA genotypes, functional and
genetic aspects of the complement system, ADAMTS13 activity and screening for autoantibodies.
The daughter was heterozygous carrier of the complement factor I G261D mutation, previously described in
patients with membranoproliferative glomerulonephritis and atypical haemolytic uremic syndrome. The mother was
non-carrier of this mutation. They shared the disease associated complement factor H silent polymorphism Q672Q
(79602A>G).
Conclusion: An unequivocal functional or molecular association between these two family cases was not found
suggesting that the patients probably share another, so far undiagnosed and unknown, predisposing factor. It
seems highly unlikely that two infrequent immunologic diseases would occur by unrelated pathophysiological
mechanisms within first degree relatives.
Keywords: Aetiology, Anti-glomerular basement membrane glomerulonephritis, Atypical haemolytic-uremic
syndrome, Thrombotic microangiopathyBackground
Goodpasture’s disease or anti-glomerular basement
membrane glomerulonephritis (anti-GBMGN) has an in-
cidence around one/million/year [1]. Autoantibodies are
directed against epitope(s) in the glomerular basement
membrane, in response to unknown stimuli [2]. It occurs
in siblings and twins and a strong association with the
major histocompatibility complex class II gene HLA
DR2, different HLA DRB1 genes, HLA DR15 and DR4* Correspondence: thomas.idorn@rh.regionh.dk
1Department of Nephrology, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen , Denmark
Full list of author information is available at the end of the article
© 2012 Idorn et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhas been reported, while DR1 and DR7 seem to protect
[3,4].
Thrombotic microangiopathy (TMA) is characterized by
haemolytic anaemia, thrombocytopenia and organ injury
due to platelet thrombosis in the microcirculation. Depend-
ing on predominantly kidney or CNS location, it is classi-
fied as haemolytic-uremic syndrome (HUS) or thrombotic
thrombocytopenic purpura (TTP). HUS may be typical
HUS or atypical HUS (aHUS) including the pregnancy
induced form. The incidence of acquired TMA is 17.5/mil-
lion/year, 17% occur during pregnancy or postpartum [5].
aHUS has defects in complement regulation causing
increased alternative pathway activation in glomerular ves-
sels. The causes are disabling mutations in the genes oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(MCP; CD46), complement factor I (CFI) and thrombomo-
dulin (THBD), and enabling mutations in factor B and C3
[6]. Autoantibodies against CFH sometimes occur [7].
Dense deposit disease (formerly membranoproliferative
glomerulonephritis type II) and C3 glomerulonephritis are
also associated with uncontrolled complement activation
and mutations in CFH or CFI have been described [8]. The
same mutations have occasionally been found in both C3
glomerulonephritis and aHUS [9]. This, in combination
with incomplete penetrance of aHUS, indicates that other
genetic or environmental factors trigger these diseases.
Anti-GBMGN has been associated with TMA (in par-
ticular TTP) and immune complex glomerulonephritis.
Both diseases were diagnosed in the same person, typic-
ally with TMA diagnosed shortly after anti-GBMGN
debut [10,11]. To our knowledge anti-GBMGN has
never been associated with aHUS and anti-GBMGN and
TMA has never been described within families. We
present a daughter and her biological mother diagnosed
with pregnancy-induced TMA and anti-GBMGN re-
spectively, with 14 years in between and describes our




A 22-year-old female was admitted with acute kidney fail-
ure following abruptio placentae causing severe vaginal
haemorrhage in gestation week 33, resulting in stillbirth.
The patient had a history of abortions in gestation weeks 9
and 28. Placental infarction at the second miscarriage
resulted in heparin treatment during the actual pregnancy,
which had been normotensive without proteinuria 2 days
before admission.
She presented with haemolytic anaemia, thrombocy-
topenia, schistocytes, uraemia, hypertension, oliguria and
proteinuria (Table 1). Treatment included plasmapheresis,
haemodialysis and glucocorticoids. Anti-cardiolipin immu-
noglobulins, anti-Scl-70 and anti-double stranded DNA
were negative. Anti-GBM and ANCA titers were not
examined at disease onset, but were negative when exam-
ined 14 years later. Renal biopsy showed necrotic glomeruli
with thrombi, platelet deposits and fibrin, vascular changes
with luminal narrowing and intimal thickening, but no
deposits. The diagnosis was TMA (pathologist Thomas
Horn, MD, DMSc, Herlev Hospital, Denmark) (Figure 1).
A grand mal seizure occurred during hospitalization (no
simultaneous metabolic derangements or severe hyperten-
sion). The clinical diagnosis was pregnancy-induced TMA
with components of aHUS and TTP. After 6 months,
kidney function improved and the patient was temporarily
dialysis-independent for three years. She was never
transplanted.Mother
A 69-year-old female was admitted with anuria and acute
kidney failure. The patient had a 6-year hypertension his-
tory, hypothyroidism for 30 years and a minor stroke
4 months earlier treated by carotid thrombendarterect-
omy. At that time p-creatinine was normal. Blood tests
showed severe uraemia and anaemia, but no haemolysis
(Table 1). The anti-GBM titer was positive, 95 U/mL
(ELISA-kit, Wieslab, Sweden; ELISA-reader TECAN,
Switzerland) and myeloperoxidase anti-neutrophil cyto-
plasmic antibodies titer (MPO ANCA) was 25 U/mL.
Proteinase-3 ANCA was negative (ELISA-reader TECAN,
Switzerland) and chest X-ray normal. Treatment included
methylprednisolone, cyclophosphamide, plasmapheresis
and haemodialysis. Renal biopsy showed diffuse extraca-
pillary glomerulonephritis with predominantly fresh cres-
centic formations, focal and segmental necrosis and linear
deposition of IgG along the glomerular basement mem-
brane, consistent with anti-GBMGN (pathologist Claus B.
AndersenMD, DMSc, Rigshospitalet, Denmark) (Figure 2).
The anti-GBM and MPO ANCA titres normalised after
16 days. There were no signs of TMA at any time. Kidney
function was not regained.
Additional analyses
Following maternal diagnosis, additional information
was obtained and the following analyses were done:
Family history: Further elaboration of the family history
of kidney disease was done in order to identify
additional cases. No other family members had ever
experienced clinically significant kidney diseases or any
signs of kidney disease. It was not possible to obtain
blood samples for genetic analyses from the father.
Mother and daughter lived in the same household until
a few years before disease onset of the daughter. There
were no obvious exposures to environmental factors
such as drugs, hydrocarbons or other toxins. They
discharged different occupations.
HLA tissue typing (Dynabeads, Dynal, Norway): HLA-
A1,26;B7,8;DR2,3 (mother), HLA-A1;B8,37;Cw6;DR3,6
(daughter). Subtyping was not performed.
ADAMTS13 activity and antibodies (CytoFlourW 4000
Fluorescence Plate Reader, Applied Biosystems Inc,
USA): ADAMTS13-protein 0.61 U/L (0.75-1.33)
(mother); 0.97 U/L (daughter). No antibodies.
The complement system (Wielisa, Wieslab, Sweden):
Both patients had normal alternative- and classical
pathway function. The daughter had reduced
Mannose-binding lectin (MBL) pathway activity, and
additional gene typing (SSP-PCR) revealed gene type
XA/B, compatible with a severely reduced MBL level.
Gene sequencing of CFH, CFI, MCP and THBD
showed heterozygosity for a CFI mutation (G261D,
Table 1 Baseline data
Compound and Unit – SI units Reference Daughter, (TMA/aHUS) Mother, (anti-GBMGN)
Haemoglobin, mmol/L (g/L) 7.0–10.0 (113–161) 5.3 (85) 6.1 (98)
Platelets, ×109/L 150–400 46 533
Haptoglobin, μmol/L 4–23 <5 13
Lactate dehydrogenase, U/L 150–450 7724 313
Bilirubin, μmol/L 4–17 36 9
Peripheral smear >5% Schistocytes (Coombs test not performed) n/a
White blood cell count × 109/L 3.0–9.0 18.3 21.0
C-reactive protein, nmol/L <95 n/a 981
Activated partial thromboplastin time, seconds 23–35 49 26
Factor II + VII + X, U/L >0.60 1.00 0.85
Creatinine, μmol/L 40–110 430 799
Urea nitrogen, mmol/L 2.5–7.5 15.0 30.7
Potassium, mmol/L 3.5–5.0 6.6 5.9
Sodium, mmol/L 136–146 137 131
Phosphorus (inorganic), mmol/L 0,80–1,50 1,99 2,37
Calcium, mmol/L 2,20–2,60 2,18 2,15
Albumin, g/L 36–48 28 37
Bicarbonate, mmol/L 23–31 20 21
Baseline data at admission. Reference interval according to Danish standards.
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associated polymorphisms in the daughter. The mother
was non-carrier of the G261D mutation but shared the
disease associated CFH Q672Q silent polymorphism
(Table 2). CFH-autoantibodies were not investigated,
but none of the patients were carriers of the common
CFHR1/CFHR3 deletion or other CFHR1 deletions
strongly associated with antibody induced aHUS [12].
Measurement of C3 levels were not performed.Figure 1 TMA/aHUS. Light microscopy, x200, hematoxylin and
eosin stain. Thrombosis of the afferent arteriole (", large arrow) and
partial necrosis of the glomerulus with deposition of fibrin (*) and
fragmented erythrocytes (", small arrow).Conclusions
The occurrence of two very rare renal diseases within the
same family is likely to be explained by a common aeti-
ology. One linkage could be a common autoantibody-
profile; however this was not demonstrated. ANCA-
positive testing in anti-GBMGN occurs in 30% [13] and
HLA tissue typing demonstrated known predisposing rela-
tions without any conspicuous shared patterns. The
mother’s slightly reduced ADAMTS13-protein is probablyFigure 2 anti-GBMGN. Light microscopy, x200, hematoxylin and
eosin stain. Diffuse extracapillary glomerulonephritis with
predominant fresh crescentic formations (*) and a few older
cresentic formations with fibrosis (**). Compression of the preserved
part of glomeruli (").
Table 2 Genetic analyses
Gene Variation Description Disease association Daughter, (TMA/aHUS) Mother (anti-GBMGN)
CFI NG_007569
c.5256A>G Intron rs7671905 Polymorphism homozygous homozygous
c.42455C>T Intron rs79375065 Polymorphism heterozygous Non-carrier
c.46524G>A Intron rs4382037 Polymorphism homozygous homozygous
c.46615G>A G261D Mutation reported in MPGN and aHUS heterozygous Non-carrier
c.49140C>A Intron rs7437142 Polymorphism homozygous homozygous
c.49159ins AATTT Intron rs78629056 Polymorphism homozygous homozygous
c.57335C>G Intron rs7441380 Polymorphism homozygous homozygous
c.66205C>T Intron rs551 Polymorphism homozygous homozygous
CFH NG_007259.1
c.38184A>C A307A Disease risk polymophism (AMD) heterozygous Non-carrier
c.43097C>T H402Y Disease risk polymophism (AMD) heterozygous Non-carrier
c.79602A>G Q672Q Disease risk polymorphism (aHUS) heterozygous heterozygous
c.89786C>A Intron rs375046 Polymorphism heterozygous heterozygous
c.93634G>T E936D Disease risk polymorphism (aHUS) heterozygous Non-carrier
MCP NG_009296
c.12610A>G L139L rs12126088 Rare non-Disease Causing Polymorphism heterozygous Non-carrier
c.20790G>T Intron rs2724374 Polymorphism heterozygous Non-carrier
c.36158G>A Intron rs1962149 Polymorphism heterozygous Non-carrier
THBD NG_012027
c.6578C>T A473V rs1042579 Polymorphism homozygous heterozygous
Genetic screening for variation in the CFI-, CFH-, MCP- (CD46) and THBD-genes. Position of the variations in the respective GeneBank refrence sequences as well as
dbSNP numbers are listed.
CFI = Complement Factor I, CFH = Complement Factor H, MCP = Membrane Cofactor Protein, THBD = Thrombomodulin, AMD = Age-related Macula Degeneration.
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ADAMTS13 activity and antibody absence during screen-
ing, does not exclude affection at diagnosis. The daugh-
ter’s G261D CFI-gene mutation combined with disease-
associated polymorphisms may predispose to the
pregnancy-induced TMA. The G261D mutation has been
found in other patients with C3 glomerulonephritis and
aHUS [9,14]. Despite several tests by Nilsson et al., no
functional effect of the G261D mutation on CFI mediated
complement regulation or on CFI serum levels could be
demonstrated [14]; however, it may have effects not
revealed by the in vitro tests, or be a marker for a linked
genetic deficiency. The silent G672G polymorphism in
both patients is strongly associated with aHUS [15], and
even though this is unlikely to be the shared aetiology, it is
possible that it influenced the disease in both patients.
Reduced MBL activity was demonstrated in the daughter
but not the mother. This has no known relation to TMA
(or anti-GBMGN).
In conclusion, we have found a shared CFH polymorph-
ism that may confer increased complement-mediated dis-
ease risk, but no other connection between TMA and
anti-GBMGN. The diseases may require multiple triggers
including mutations, polymorphisms, autoantibodies andperhaps infections, and a common genetic susceptibility
cannot be ruled out.
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